Journal of Medicinal Chemistry · 2004 · 58 citations · 9 references
MedicineNeurosciencePharmacologyDrug DiscoveryMolecular PharmacologyNeuropharmacologyAntipsychotic PharmacologyGlutamatergic PharmacologyGlutamatergic SignalingAllosteric MechanismsMetabotropic Glutamate Receptor SignalingMetabotropic ReceptorsNeurotransmitter Receptor PharmacologyPharmacology Of Glutamate ReceptorsPositive Allosteric ModulationPositive Allosteric ModulatorsReceptors
Herein we disclose the discovery of a new class of positive allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2), phenyl-tetrazolyl acetophenones, e.g. 1-(2-hydroxy-3-propyl-4-[4-[4-(2H-tetrazol-5-yl)phenoxy]butoxy]phenyl) ethanone (4). These potentiators were shown to have no effect in the absence of glutamate as well as no effect at mGlu3 or the other mGlu receptors. The compounds were also evaluated in rodent models with potential relevance for schizophrenia, and 4 was shown to have activity in the inhibition of ketamine-induced norepinephrine release and ketamine-induced hyperactivity. This represents the first example of the efficacy of mGlu2 receptor potentiators in these models.
9
Daniel S. Lorrain, Christopher Baccei, Linda J. Bristow et al. · Neuroscience · 2003 · 431 citations
Frédéric Knoflach, Vincent Mutel, Synèse Jolidon et al. · Proceedings of the National Academy of Sciences · 2001 · 236 citations · Full text
Medicine, Neuroscience, Pharmacology +17